Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?
- 21 November 2020
- journal article
- Published by Publishing House OKI in Antibiotics and Chemotherapy
- Vol. 65 (7-8), 52-62
- https://doi.org/10.37489/0235-2990-2020-65-7-8-52-62
Abstract
Rifaximin is an antibiotic characterized by polymorphism. It has various crystalline forms with different pharmacological characteristics. Rifaximin acts locally in the digestive tract, therefore it is important for the absorption to be minimal and for concentration in the intestinal lumen to be high. The absorption of other crystalline forms of rifaximin in the intestine is greater than that of rifaximin-α (Alpha Normix®). Differences in pharmacokinetics of the crystalline forms of rifaximin may affect its effectiveness and safety, especially in patients with chronic diseases (immunodeficiency and leaky gut against the background of liver cirrhosis) who require long courses of therapy. Rifaximin-α (Alpha Normix®) is unique as it has eubiotic and anti-inflammatory properties in addition to local antibacterial effect. Given its diverse mechanisms of action, rifaximin-α positively modulates gut microbiota.Keywords
This publication has 67 references indexed in Scilit:
- Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic EncephalopathyPLOS ONE, 2013
- Rifaximin in irritable bowel syndrome: rationale, evidence and clinical useTherapeutic Advances in Chronic Disease, 2013
- Pregnane X receptor as a target for treatment of inflammatory bowel disordersTrends in Pharmacological Sciences, 2012
- Rifaximin for the treatment of acute infectious diarrheaTherapeutic Advances in Gastroenterology, 2011
- Rifaximin Therapy for Patients with Irritable Bowel Syndrome without ConstipationThe New England Journal of Medicine, 2011
- Pre-Steady-State Kinetic Analysis of the Incorporation of Anti-HIV Nucleotide Analogs Catalyzed by Human X- and Y-Family DNA PolymerasesAntimicrobial Agents and Chemotherapy, 2011
- Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor ActivationThe Journal of pharmacology and experimental therapeutics, 2010
- Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization ProfilesAntimicrobial Agents and Chemotherapy, 2010
- Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver diseaseJournal of Hepatology, 2009
- Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivativeDiagnostic Microbiology and Infectious Disease, 1993